28 results about "Oculopathy" patented technology

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, a preparation method therefor and the use thereof. The compound (I) has a good TSHR antagonistic effect, and is used for treating thyroid-associated disorders and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and for preparing drugs for such disorders or diseases.

The invention relates to a construction method of a thyroid-related eye disease animal model, and belongs to the technical field of biology. The invention provides a thyroid-associated ophthalmopathy animal model construction method, which comprises: (1) separating and purifying in vitro peripheral blood collected from a thyroid-associated ophthalmopathy patient to obtain an exosome; and (2) injecting the exosome into a to-be-modeled animal to prepare the thyroid-associated ophthalmopathy animal model. According to the invention, exosomes are extracted from in-vitro peripheral blood of patients with thyroid-associated ophthalmopathy and are injected into animals, so that the thyroid-associated ophthalmopathy animal model with a plurality of pathological characteristics such as orbital tissue inflammatory response, fibrosis, orbital lesion, thyroid dysfunction and the like is successfully constructed; the method can be widely applied to pathological mechanism research of thyroid-related eye diseases and screening and evaluation of thyroid-related eye disease treatment drugs.

The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), or a symptom or aspect thereof, in subjects that have undergone prior treatment for TAO, TED, or GO, and either did not respond to said prior treatment or relapsed after said prior treatment. The invention also provides antibodies, or antigen binding fragments thereof, and pharmaceutical compositions useful in the disclosed methods.

A method of monitoring an overall thyroid ophthalmopathy treatment includes requesting a user device to take a facial image and enter a questionnaire survey content according to treatment monitoring cycle; obtaining the facial image and the questionnaire survey content from the user device; obtaining, using the facial image and the questionnaire survey content obtained from the user device, a personalized estimate of the user corresponding to exophthalmos information, CAS (Clinical Activity Score) information, and diplopia information among an indicator proven at an approval stage of the medicine; and displaying, which comprises visualizing the personalized estimate of the user in a time-series order from the time the user started administering the medicine on the user device.

The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), or a symptom or aspect thereof, in subjects that have undergone prior treatment for TAO, TED, or GO, and either did not respond to said prior treatment or relapsed after said prior treatment. The invention also provides antibodies, or antigen binding fragments thereof, and pharmaceutical compositions useful in the disclosed methods.

The invention discloses a negative ion metabolism marker for thyroid-associated ophthalmopathy, a product and application of the negative ion metabolism marker. The metabolic marker is prepared from any one or more of 7alpha, 17alpha-dimethyl-5beta-androstane-3 alpha, 17beta-diol, N, N-dimethyl phosphatidyl ethanolamine, 15 (S)-hydroxy eicosatrienoic acid and 1-myristoyl-2-[(9Z)-octadecenoyl]-sn-glycerol-3-phosphatidylcholine, and the metabolic marker is prepared from any one or more of the following raw materials: 1-myristoyl-2-[(9Z)-octadecenoyl]-sn-glycerol-3-phosphatidylcholine. The invention provides a kit which comprises a detection reagent for detecting the negative ion metabolism marker. The invention provides a computer program product for thyroid-related eye diseases. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of thyroid-related eye diseases, and provides a new tool for clinical diagnosis.

Provided herein are methods of treating or reducing the severity of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

The invention provides a method of reducing the severity of, or treating, thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

A method of monitoring an overall thyroid ophthalmopathy treatment includes requesting a user device to take a facial image and enter a questionnaire survey content according to treatment monitoring cycle; obtaining the facial image and the questionnaire survey content from the user device; obtaining, using the facial image and the questionnaire survey content obtained from the user device, a personalized estimate of the user corresponding to exophthalmos information, CAS (Clinical Activity Score) information, and diplopia information among an indicator proven at an approval stage of the medicine; and displaying, which comprises visualizing the personalized estimate of the user in a time-series order from the time the user started administering the medicine on the user device.

The present invention provides a method and apparatus for identifying thyroid-related ophthalmopathy based on eye CT images. The method includes: obtaining a plurality of slice images of an eye image; screening the plurality of slice images to obtain target CT slice images, where the target CT slice images are CT slice images that can be used to judge thyroid-related ophthalmopathy; segmenting each of the target CT slice images to extract contour location information of the eyeball and the orbit in each of the target CT slice images; and obtaining an identification result of thyroid-related ophthalmopathy based on the contour location information of the eyeball and the orbit. In the embodiments of the present invention, by automatically screening and identifying a plurality of slice images, not only the number of annotations is reduced, the development cost is saved, but also the diagnosis efficiency of thyroid-related ophthalmopathy is improved.

A method of monitoring an overall thyroid ophthalmopathy treatment includes requesting a user device to take a facial image and enter a questionnaire survey content according to treatment monitoring cycle; obtaining the facial image and the questionnaire survey content from the user device; obtaining, using the facial image and the questionnaire survey content obtained from the user device, a personalized estimate of the user corresponding to exophthalmos information, CAS (Clinical Activity Score) information, and diplopia information among an indicator proven at an approval stage of the medicine; and displaying, which comprises visualizing the personalized estimate of the user in a time-series order from the time the user started administering the medicine on the user device.

The application belongs to the technical field of biological medicine, and relates to a construction method of a thyroid-associated ophthalmopathy animal model, which comprises the following steps: after a pseudo-sterile animal model is constructed, fecal bacteria liquid of a mild patient with thyroid-associated ophthalmopathy is first administered to the pseudo-sterile animal model in a first stage, and Ad-TSHR is injected once in the second half of the first stage; then fecal bacteria liquid of a moderate patient with thyroid-associated ophthalmopathy is administered to the pseudo-sterile animal model in a second stage, and Ad-TSHR is injected once in the second half of the second stage; then fecal bacteria liquid of a severe patient with thyroid-associated ophthalmopathy is administered to the pseudo-sterile animal model in a third stage, and Ad-TSHR is injected once in the second half of the third stage; finally, Ad-TSHR is injected once in the second half of a fourth stage; and thus the thyroid-associated ophthalmopathy animal model is obtained. The model has a high incidence of 80% and a significantly reduced mortality rate under the condition of less immunization times.

A method of monitoring an overall thyroid ophthalmopathy treatment includes requesting a user device to take a facial image and enter a questionnaire survey content according to treatment monitoring cycle; obtaining the facial image and the questionnaire survey content from the user device; obtaining, using the facial image and the questionnaire survey content obtained from the user device, a personalized estimate of the user corresponding to exophthalmos information, CAS (Clinical Activity Score) information, and diplopia information among an indicator proven at an approval stage of the medicine; and displaying, which comprises visualizing the personalized estimate of the user in a time-series order from the time the user started administering the medicine on the user device.

The invention discloses application of sitagliptin in preparation of a medicine for treating Graves eye diseases, and belongs to the field of biological medicine. The invention discloses the application of sitagliptin in preparation of the medicine for treating Graves eye diseases for the first time, and sitagliptin can improve expression of CD4 + CTL cytotoxic functional molecules and improve eye symptoms, extraocular muscle thickening and fibrosis, orbit fat neogenesis and orbit T lymphocyte infiltration of mice; the mouse spleen CD4 + CTL cell proportion is improved; in addition, the thyroid hormone level, thyroid hyperplasia and hypertrophy and lymphocyte infiltration of mice can be improved. Sitagliptin is a clinically common hypoglycemic drug, and is perfect in safety database, small in side effect and easy to popularize clinically. Therefore, the experimental result of the invention fully supports the new application of sitagliptin in treating Graves eye diseases, and is a new direction worthy of exploration for treating Graves eye diseases due to strong clinical operability.

Proposed is a method of monitoring an overall thyroid ophthalmopathy treatment, the method comprising: during a treatment period in which a user is prescribed and administered a medicine that has been proven to be effective in treating thyroid ophthalmopathy treatment through clinical trials, requesting a user device to take a facial image and enter a questionnaire survey content according to treatment monitoring cycle; obtaining the facial image and the questionnaire survey content from the user device; obtaining, using the facial image and the questionnaire survey content obtained from the user device, a personalized estimate of the user corresponding to exophthalmos information, CAS(Clinical Activity Score) information, and diplopia information among an indicator proven at an approval stage of the medicine; and displaying, which comprises visualizing the personalized estimate of the user in a time-series order from the time the user started administering the medicine on the user device; after the treatment period is ended, requesting the user device to take the facial image according to a post-treatment monitoring cycle; obtaining the facial image from the user device; obtaining the personalized estimate of the user corresponding to at least the exophthalmos information by using the facial image obtained from the user device; displaying, which comprises visualizing the personalized estimate of the user corresponding to the exophthalmos information by comparing with the exophthalmos information at the end of the administration of the medicine on the user device; and displaying a message about a suggestion to visit a hospital based on a difference between the personalized estimate of the user corresponding to the exophthalmos information and the exophthalmos information at the end of the administration of the medicine.

An aspect relates to a biomarker for diagnosing thyroid-associated ophthalmopathy and use thereof. According to an aspect, by measuring the expression levels of: one or more genes selected from the group consisting of Sox6 gene, Eya1 gene, Six1 gene, and Nfix gene; a polynucleotide encoded by the gene; and a biomarker comprising a polypeptide or fragment thereof, it is possible to accurately and rapidly diagnose thyroid-associated ophthalmopathy. In addition, by using the biomarker, not only thyroid-associated ophthalmopathy but also muscle hypertrophy or muscle fibrosis caused by thyroid-associated ophthalmopathy can be diagnosed early, thereby preventing ocular proptosis, strabismus, diplopia, vision deterioration, blindness, or the like. Furthermore, a therapeutic agent for thyroid-associated ophthalmopathy can be screened by using the biomarker, and the biomarker can be used for treating thyroid-associated ophthalmopathy through adjustment of the expression level thereof.

The invention discloses an application of a prostaglandin EP4 receptor stimulant in a preparation for preventing or treating thyroid-associated ophthalmopathy, belongs to the technical field of biological medicines, and aims to find a new and completely effective preparation for locally inhibiting orbit fat hyperplasia. The 3D cell culture technology closer to the in-vivo environment is used for exploring the influence of the prostaglandin EP4 receptor agonist L-902688 on adipogenic differentiation of TAO patient eye socket adipose-derived mesenchymal stem cells (OASCs), and the result shows that the L-902688 can significantly promote brown adipose differentiation and increase lipid hydrolysis and consumption, can effectively reduce fat accumulation and does not promote secretion of inflammatory factors. The results provide a new treatment thought for clinical treatment of TAO.

The invention discloses a positive ion metabolism marker for thyroid-associated ophthalmopathy, a product and application of the positive ion metabolism marker. The positive ion marker is prepared from any one or more of L-arginine-L-valeryl-L-lysine, cholesterol beta-epoxide, phosphatidylcholine (18: 4 / 20: 5), sphingosine galactoside and oestrone. The invention provides a kit which comprises a detection reagent for detecting the positive ion marker. A computer program product associated with thyroid-related ocular diseases is provided. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of thyroid-related eye diseases, and provides a new tool for clinical diagnosis.

A method of monitoring an overall thyroid ophthalmopathy treatment includes requesting a user device to take a facial image and enter a questionnaire survey content according to treatment monitoring cycle; obtaining the facial image and the questionnaire survey content from the user device; obtaining, using the facial image and the questionnaire survey content obtained from the user device, a personalized estimate of the user corresponding to exophthalmos information, CAS (Clinical Activity Score) information, and diplopia information among an indicator proven at an approval stage of the medicine; and displaying, which comprises visualizing the personalized estimate of the user in a time-series order from the time the user started administering the medicine on the user device.

The present application relates to a kind of deep learning method based on SPECT / CT detection thyroid-related eye disease activity, including two stages of eye muscle segmentation stage and activity staging classification, in the eye muscle segmentation stage, first, the CT image of eye is three-dimensional reconstruction, and training eye muscle semantic segmentation model, finally using the eye muscle segmentation model of well-trained in test set eye muscle mask;In the classification stage of judging whether thyroid-related eye disease is in active period, three-channel data are formed by using eye muscle mask, SPECT and CT image, and three-channel data are used to train classification model, SPECT / CT image and the eye muscle mask of patient are combined into three-channel image and input into classification model, and finally the activity of thyroid-related eye disease is output by the trained classification model.Through the deep learning method of two stages, the activity of thyroid-related eye disease is automatically classified.

The present invention provides a TSHR antagonist compound of formula (I), a pharmaceutical composition, a method for preparing same, and use thereof. The compound has a good TSHR antagonistic effect and is used for treating thyroid-related disorders and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid-associated ophthalmopathy, and for preparing a medicament for such disorders or diseases.

The invention provides a thyroid-related eye disease mouse model evaluation method. The thyroid-related eye disease mouse model evaluation method comprises the following steps: S1, appearance phenotype evaluation; s2, thyroid function index evaluation; s3, carrying out iconography evaluation; s4, performing immunological phenotype evaluation; and S5, carrying out histopathologic evaluation. Compared with a traditional research method only paying attention to single eye phenotype or single histological change, the thyroid-related eye disease mouse model evaluation method provided by the invention comprehensively reflects disease characteristics of a TAO mouse model from five dimensions of appearance phenotype, thyroid function, immune phenotype, histopathology and iconography; multi-dimensional comprehensive evaluation of the TAO mouse model is realized, and a scientific, comprehensive and standardized evaluation method is established.

The application discloses a negative ion metabolic marker of thyroid-associated ophthalmopathy, a product and application thereof. The metabolic marker comprises any one or several of 7alpha, 17alpha-dimethyl-5beta-androstane-3alpha, 17beta-diol, N, N-dimethylphosphatidyl ethanolamine, 15(S)-hydroxyeicosatrienoic acid and 1-tetradecanoyl-2-[(9Z)-octadecenoyl]-sn-glycero-3-phosphatidylcholine. The application provides a kit comprising detection reagents for detecting the negative ion metabolic marker. The application provides a computer program product for thyroid-associated ophthalmopathy. The product provided by the application has good feasibility and accuracy, can effectively evaluate the risk of thyroid-associated ophthalmopathy, and provides a new tool for clinical diagnosis.

Disclosed herein are compounds useful for the inhibition of insulin-like growth factor 1 receptor (IGF-1R). The compounds have a general Formula (I): or pharmaceutically acceptable salts thereof, wherein the variables of Formula (I) are as defined herein. Also provided herein are pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, thyroid-associated ophthalmopathy, Graves' opthalmopathy or Graves' orbitopathy. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).

The invention relates to a nucleic acid aptamer for targeting CD34 positive orbit fibroblasts, which is characterized in that the nucleotide sequence of the nucleic acid aptamer is as shown in SEQ ID NO: 16. The nucleic acid aptamer provided by the invention has the advantages of high affinity, strong specificity, small molecular weight, good stability, simple synthesis, low cost, easy modification, no immunogenicity and the like, and can meet the requirements of rapid detection of thyroid-related ophthalmopathy at present.

The present invention addresses the problem of providing a novel compound that has thyroid-stimulating hormone receptor antagonist activity and is useful for treating thyroid-related diseases.　The present invention pertains to a biaryl compound represented by formula (I) or a pharmacologically acceptable salt thereof. The compound according to the present invention or the pharmacologically acceptable salt thereof has antagonist activity with respect to thyroid-stimulating hormone receptors, and is therefor useful as a therapeutic agent and the like for thyroid-related diseases (for example, hyperthyroidism, Graves disease, thyroid-associated ophthalmopathy, and thyroid cancer).

The application discloses a microbial marker of thyroid-associated ophthalmopathy, a product and application thereof, and belongs to the field of biological medicine. The microbial marker comprises one or more of Faecalibacterium prausnitzii, Parabacteroides sp. CT06, Escherichia coli, Alistipes finegoldii and Bacteroides uniformis. The application provides a kit comprising detection reagents for detecting the relative abundance of the microbial marker. The product provided by the application has good feasibility and accuracy, can effectively evaluate the risk of thyroid-associated ophthalmopathy, and provides a new tool for clinical diagnosis.

A method for treating a subject having a retinal eye condition that is refractory to anti-VEGF treatments is disclosed. The method comprises administering a therapeutically effective amount of one or more steroids subsequent to anti-VEGF treatment, thereby treating the retinal eye condition. Also disclosed is a method for treating a subject having a retinal eye condition that is refractory to anti-VEGF treatments, the method comprising a therapeutically effective amount of one or more compounds capable of modulating an activity of a steroid receptor, subsequent to anti-VEGF treatment. Further disclosed is a method for treating a subject having a retinal eye condition that is refractory to anti-VEGF treatments comprising administering a therapeutically acceptable formulation of a steroid, and at least a second therapeutically active compound in a concentration and dose sufficient to ameliorate the retinal eye condition, subsequent to anti-VEGF treatment.